TIV did not provide any protection against hospitalization in pediatric subjects, especially children with asthma. On the contrary, we found a threefold increased risk of hospitalization in subjects who did get the TIV vaccine.
Over the following 9 months, TIV recipients had an increased risk of virologically-confirmed non-influenza infections (relative risk: 4.40; 95% confidence interval: 1.31-14.8). Being protected against influenza, TIV recipients may lack temporary non-specific immunity that protected against other respiratory viruses.
“In addition, because of the order of magnitude increase in fetal-loss report rates, from 6.8 fetal loss reports per million pregnant women vaccinated in the single-dose 2008/2009 season to 77.8 in the two-dose 2009/2010 season, further long term studies are needed to assess adverse outcomes in the surviving children. Additional research concerning potential synergistic risk factors associated with the administration of Thimerosal-containing vaccines is warranted, and the exposure-effect association should be verified in further toxicological and case-control studies.”
The current influenza vaccine program seems to be ineffective, and the U.S. should consider replacing it with a program based primarily on antiviral medications. Research is needed to develop more and better antivirals, especially agents to which influenza viruses do not readily develop resistance.
Definitely. Always be skeptical. I’m having trouble locating the 600%, but I will keep looking.
Meanwhile, here are some related articles:
https://pubmed.ncbi.nlm.nih.gov/22525386/
https://pubmed.ncbi.nlm.nih.gov/22423139/
https://www.jpands.org/vol11no3/geier.pdf